The EVEREST II trial has shown the MitraClip has similar mortality rate to that of surgery and, on the other hand, we are well aware that residual mitral regurgitation (MR) is associated with a strong negative impact. However, research has shown little about transvalvular gradient after MitraClip and what it entails. 268 patients receiving MitraClip were<a href="https://solaci.org/en/2022/06/03/post-mitraclip-mitral-valve-stenosis-bad-prognosis/" title="Read more" >...</a>
At present, we are well aware of the rise in mortality caused by severe tricuspid regurgitation (TR). Medical and surgical treatments have turned out to be suboptimal. Hence, endovascular intervention presents as an alternative therapeutic strategy with promising results. The aim of this multicenter, prospective study was to assess the safety and efficacy of the<a href="https://solaci.org/en/2022/05/30/europcr-2022-clasp-tr-study-promising-results-of-endovascular-intervention-of-tricuspid-regurgitation/" title="Read more" >...</a>
Tricuspid regurgitation (TR) is difficult to manage and is a mortality predictor. At present, surgery is recommended, even though its mortality rate is not low. Endovascular intervention of this entity is currently being developed and according to the European guidelines, it has evidence level IIb C in symptomatic inoperable patients. The TriCLASP included 74 patients<a href="https://solaci.org/en/2022/05/26/europcr-2022-triclasp-evolution-at-30-days/" title="Read more" >...</a>
Tricuspid failure is a prevalent valvulopathy most often mistreated. It has been associated with high surgical risk and medical treatment has showed substandard therapeutic effect. Surgical repair with valve annuloplasty is the technique of choice for its long-term durability. Transcatheter repair of the tricuspid valve is an alternative that aims at imitating annuloplasty by reducing<a href="https://solaci.org/en/2022/05/24/europcr-2022-1-year-outcomes-of-tricuspid-valve-repair-with-cardioband-feasibility-study/" title="Read more" >...</a>
In ST elevation MI, the common assessment methodology continues to the angiography; however, we all know it has certain limitations, especially when it comes to intermediate lesions or coronary dissections. Using imaging, especially high resolution such as OCT, has been looked into by some studies, but never randomized studies. The EROSION III is a randomized<a href="https://solaci.org/en/2022/05/10/should-we-start-using-oct-in-myocardial-infarction-with-non-obstructive-lesions/" title="Read more" >...</a>
Intravascular ultrasound (IVUS) to guide drug-eluting stent (DES) implantation has been evaluated in several studies. Two randomized studies, IVUS-XPL (Impact of Intravascular Ultrasound Guidance on the Outcomes of Xience Prime Stents in Long Lesions) and ULTIMATE (Intravascular Ultrasound Guided Drug Eluting Stents Implantation in All-Comers Coronary Lesions), have shown fewer repeat revascularizations compared with angiography-guided<a href="https://solaci.org/en/2022/05/02/ivus-guided-coronary-angioplasty-promising-results-at-3-year-follow-up/" title="Read more" >...</a>
Same-day discharge (SDD) has been shown to be effective in angioplasties and some peripheral procedures, but the pandemic—because of the burden it caused on the healthcare system—has forced the optimization of hospitalization times for other pathologies and procedures. This strategy is yet to be tested in transcatheter aortic valve replacement (TAVR) due to the possible<a href="https://solaci.org/en/2022/04/01/same-day-discharger-after-tavr-are-we-there-yet/" title="Read more" >...</a>
Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical treatment these days is not exactly low, involving high risk, which often takes this alternative off the table. Several percutaneous devices have been developed to treat this disease, the most popular being edge-to-edge devices. The TRICENTO has an<a href="https://solaci.org/en/2022/03/25/tricento-promising-results-for-severe-tricuspid-valve-regurgitation/" title="Read more" >...</a>
The benefit of first-generation Drug-Eluting Stents (DES) over Bare Metal Stents (BMS) is largely known. Moreover, technological developments have led to reduced strut size, biodegradable polymers, and new scaffolds, which in turn have led to improved outcomes. These are known as ultrathin stents, and its struts measure between 70 and 100 microns, which contributes to<a href="https://solaci.org/en/2022/03/23/drug-eluting-stents-does-strut-size-matter/" title="Read more" >...</a>
Bicuspid aortic valve malformation is the most frequent cardiac malformation (about 1%), and a significant percentage of these cases generate severe aortic stenosis. As we know, transcatheter aortic valve replacement (TAVR) has been developed for tricuspid valves, which are studied in the most important randomized trials for high-, medium-, and low-risk patients. While current information<a href="https://solaci.org/en/2022/03/16/are-expandable-balloon-valves-an-option-for-the-bicuspid-valve-in-low-risk-patients/" title="Read more" >...</a>